权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Targeting IDH mutations to improve seizure control in glioma patients

针对 IDH 突变改善神经胶质瘤患者的癫痫发作控制

基本信息

批准号：
10612395
负责人：
Craig Michael Horbinski
金额：
$ 43.25万
依托单位：
NORTHWESTERN UNIVERSITY AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-08-01 至 2025-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10612395
关键词：
Address Adult Affect Agonist Alzheimer&apos s Disease Antiepileptic Agents Anxiety Behavior Binding Brain Brain Neoplasms Cells Characteristics Chemicals Clinical Clinical Trials Coculture Techniques DNA Sequence Alteration Data Disease Electroencephalography Engineering Engraftment Enzyme Inhibitor Drugs Epilepsy Excitatory Amino Acid Transporter 2 Extracellular Space Fostering Generations Genes Genomics Genotype Glioblastoma Glioma Glutamate Transporter Glutamates Hippocampus Immunohistochemistry In Vitro Incidence Inflammation Isocitrate Dehydrogenase Keppra Left Levetiracetam Life Link Mass Spectrum Analysis Memantine Membrane Memory Loss Metabolic Methods Molecular Mus Mutation N-Methyl-D-Aspartate Receptors NMDA receptor antagonist Neurologic Neurons Neurotransmitters Oranges Oxidative Stress Pathologic Patients Persons Pharmaceutical Preparations Predisposition Preparation Primary Brain Neoplasms Production Proteomics Publishing Quality of life Receptor Down-Regulation Receptor Inhibition Risk Seizures Sleeping Beauty Slice Synaptic Cleft Testing Time Tissues Transposase United States Work World Health Organization analog antagonist brain tissue comparison control efficacy evaluation epileptiform excitatory amino acid transporter 3 excitotoxicity experience improved in vivo inhibitor multi-electrode arrays neural neuron loss new therapeutic target next generation patch clamp patient population pharmacologic postsynaptic prevent receptor receptor downregulation reuptake side effect success transcriptome sequencing tumor

项目摘要

PROJECT SUMMARY Diffusely infiltrative glioma is the most common primary brain tumor in adults. Most glioma patients experience at least one seizure during the course of their disease, and over 30% suffer from repeated seizures, known as tumor-associated epilepsy (TAE). Current front-line treatment for TAE is levetiracetam (LEV) (a.k.a. Keppra®), but this fails to control seizures in over 50% of patients. Such patients then require more powerful second-line antiepileptic drugs that often have greater side effects. TAE is more common in World Health Organization (WHO) grade II-III gliomas than in grade IV glioblastomas, but the reason for this is not clear. The vast majority of grade II-III gliomas contain mutations in isocitrate dehydrogenases 1 and 2 (collectively “IDHmut”), which lead to the production and release of large amounts of D-2-hydroxyglutarate (D2HG). D2HG bears a great deal of structural similarity to glutamate, an excitatory neurotransmitter that binds to N-methyl-D-aspartate receptor (NMDAR) on neurons. Our data show that D2HG increases in vitro neuronal membrane depolarization and neuronal network activity, and that this can be completely blocked by an NMDA receptor (NMDAR) antagonist. We also found that IDHmut glioma increases seizure activity in engrafted mice compared to IDHwt glioma, and that this is greatly reduced by treatment with IDHmut enzyme inhibitor. Finally, we found that IDHmut gliomas are much more likely to cause seizures compared to IDHwt gliomas. This is the first direct evidence of a mechanistic link between IDHmut and seizures; therefore, our hypothesis is that D2HG contributes to an increased incidence of seizures in patients with IDHmut gliomas, and that new targeted therapeutic strategies can decrease seizures in these patients. In Aim 1, we will explore the mechanisms by which D2HG triggers neuronal depolarization and increased neuronal network activity. Our two main hypotheses are: (i) D2HG directly stimulates NMDA receptors; (ii) D2HG inhibits glutamate reuptake transporters that normally prevent the pathologic accumulation of glutamate in the synaptic cleft. We will use patch clamping and multi-electrode arrays to study the effects of D2HG on the electrical activity of cultured mouse cortical neurons, as well as on mouse brain slices. In Aim 2, we will explore the effects of IDHmut glioma on the surrounding nonneoplastic tissue in vivo, focusing on changes that are characteristic of epilepsy, including neuronal loss, NMDAR downregulation, oxidative stress, inflammation, hippocampal damage, and altered mouse behavior. Results will be validated in patient-derived IDHwt and IDHmut gliomas. In Aim 3, we will compare the anti-seizure effects of two next- generation IDHmut inhibitors, AG-120 and AG-881, as well as memantine, an NMDAR antagonist that is already used to treat Alzheimer’s Disease. Each of these drugs will be tested as monotherapy and in combination with LEV. Successful completion of these Aims will establish the D2HG product of IDHmut as an epileptogenic agent, will shed more light on how IDHmut alters the nonneoplastic neural tissues surrounding glioma, and will foster clinical trials to determine the efficacy of IDHmut inhibitors, and memantine, against seizures in these patients.

项目概要弥漫浸润性神经胶质瘤是成人最常见的原发性脑肿瘤。大多数胶质瘤患者都会经历患病期间至少有一次癫痫发作，超过 30% 的人会反复癫痫发作，称为肿瘤相关性癫痫（TAE）。目前 TAE 的一线治疗方法是左乙拉西坦 (LEV)（又名 Keppra®），但这无法控制超过 50% 的患者癫痫发作。此类患者需要更强大的二线药物抗癫痫药物往往具有较大的副作用。 TAE 在世界卫生组织中更为常见 (WHO) II-III 级胶质瘤高于 IV 级胶质母细胞瘤，但其原因尚不清楚。绝大多数的 II-III 级神经胶质瘤含有异柠檬酸脱氢酶 1 和 2 的突变（统称为“IDHmut”），这导致大量 D-2-羟基戊二酸 (D2HG) 的产生和释放。 D2HG 承载了大量与谷氨酸的结构相似，谷氨酸是一种与 N-甲基-D-天冬氨酸受体结合的兴奋性神经递质（NMDAR）对神经元的作用。我们的数据表明 D2HG 增加体外神经元膜去极化神经元网络活动，并且可以被 NMDA 受体 (NMDAR) 拮抗剂完全阻断。我们还发现，与 IDHwt 神经胶质瘤相比，IDHmut 神经胶质瘤增加了移植小鼠的癫痫发作活动，并且通过 IDHmut 酶抑制剂治疗可以大大减少这种情况。最后，我们发现 IDHmut 胶质瘤是与 IDHwt 神经胶质瘤相比，更容易引起癫痫发作。这是机械论的第一个直接证据 IDHmut 与癫痫发作之间的联系；因此，我们的假设是 D2HG 有助于增加 IDHmut 神经胶质瘤患者癫痫发作的发生率，新的靶向治疗策略可以减少这些患者的癫痫发作。在目标 1 中，我们将探讨 D2HG 触发的机制神经元去极化和神经网络活动增加。我们的两个主要假设是： (i) D2HG 直接刺激 NMDA 受体； (ii) D2HG 抑制谷氨酸再摄取转运蛋白，该转运蛋白通常会阻止谷氨酸在突触间隙的病理性积累。我们将使用膜片钳和多电极阵列研究 D2HG 对培养的小鼠皮质神经元以及小鼠的电活动的影响脑切片。在目标 2 中，我们将探讨 IDHmut 胶质瘤对周围非肿瘤组织的影响体内，重点关注癫痫特征的变化，包括神经元损失、NMDAR 下调、氧化应激、炎症、海马损伤和小鼠行为改变。结果将在患者来源的 IDHwt 和 IDHmut 神经胶质瘤。在目标 3 中，我们将比较接下来两种药物的抗癫痫效果：第二代 IDHmut 抑制剂 AG-120 和 AG-881，以及美金刚（一种 NMDAR 拮抗剂）用于治疗阿尔茨海默病。这些药物中的每一种都将作为单一疗法和联合疗法进行测试水平。成功完成这些目标将使 IDHmut 的 D2HG 产品成为致癫痫剂，将进一步阐明 IDHmut 如何改变神经胶质瘤周围的非肿瘤性神经组织，并将促进确定 IDHmut 抑制剂和美金刚对这些患者癫痫发作的疗效的临床试验。

项目成果

期刊论文数量（12）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Variant allelic frequencies of driver mutations can identify gliomas with potentially false-negative MGMT promoter methylation results.

DOI：
10.1186/s40478-023-01680-0
发表时间：
2023-11-02
期刊：
Acta neuropathologica communications
影响因子：
7.1
作者：
通讯作者：

Epidemiology, biology, and management of venous thromboembolism in gliomas: An interdisciplinary review.

DOI：
10.1093/neuonc/noad059
发表时间：
2023-04
期刊：
Neuro-oncology
影响因子：
15.9
作者：
J. Jo;M. Diaz;C. Horbinski;N. Mackman;S. Bagley;M. Broekman;J. Rak;J. Perry;I. Pabinger;N. Key;D. Schiff
通讯作者：
J. Jo;M. Diaz;C. Horbinski;N. Mackman;S. Bagley;M. Broekman;J. Rak;J. Perry;I. Pabinger;N. Key;D. Schiff

Docetaxel targets aggressive methylation profiles and serves as a radiosensitizer in high-risk meningiomas.

多西他赛针对侵袭性甲基化特征，并作为高风险脑膜瘤的放射增敏剂。

DOI：
10.1093/neuonc/noac206
发表时间：
2023
期刊：
Neuro-oncology
影响因子：
15.9
作者：
Youngblood,MarkW;Tran,AnhN;Wang,Wenxia;An,Shejuan;Scholtens,Denise;Zhang,Lyndsee;O'Shea,Kaitlyn;Pokorny,JennyL;Magill,StephenT;Sachdev,Sean;Lukas,RimasV;Ahmed,Atique;Unruh,Dusten;Walshon,Jordain;McCortney,Kathleen;Wang,
通讯作者：
Wang,

Reconciling the Contemporary Molecular Diagnosis of Glioblastoma With Past Clinical Trial Data.

协调胶质母细胞瘤的当代分子诊断与过去的临床试验数据。